Abstract
AbstractThis study leverages electronic health record data in the National COVID Cohort Collaborative’s (N3C) repository to investigate disparities in Paxlovid treatment and to emulate a target trial assessing its effectiveness in reducing COVID-19 hospitalization rates. From an eligible population of 632,822 COVID-19 patients seen at 33 clinical sites across the United States between December 23, 2021 and December 31, 2022, patients were matched across observed treatment groups, yielding an analytical sample of 410,642 patients. We estimate a 65% reduced odds of hospitalization among Paxlovid-treated patients within a 28-day follow-up period, and this effect did not vary by patient vaccination status. Notably, we observe disparities in Paxlovid treatment, with lower rates among Black and Hispanic or Latino patients, and within socially vulnerable communities. Ours is the largest study of Paxlovid’s real-world effectiveness to date, and our primary findings are consistent with previous randomized control trials and real-world studies.
Publisher
Cold Spring Harbor Laboratory
Reference46 articles.
1. WHO coronavirus (COVID-19) dashboard. https://covid19.who.int/. Accessed: 2023-3-26.
2. Center for Drug Evaluation & Research. FDA updates on paxlovid for health care providers. https://www.fda.gov/drugs/news-events-human-drugs/fda-updates-paxlovid-health-care-providers. Accessed: 2023-3-26.
3. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
4. Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment — California, December 2021–May 2022
5. Effectiveness of paxlovid in reducing severe coronavirus disease 2019 and mortality in High-Risk patients;Clin. Infect. Dis,2023
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献